Cancer-Related Fatigue: Evolving Concepts in Evaluation and Treatment

Cancer

Volumn 98, Issue 9, 2003, Pages 1786-1801

  Stasi, Roberto ^a   Abriani, Luca ^d   Beccaglia, Patrizia ^d   Terzoli, Edmondo ^b   Amadori, Sergio ^c  

^a REGINA APOSTOLORUM HOSPITAL   (Italy)

^b Istituti Fisioterapici Ospedalieri ^*  (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d Janssen Cilag SpA Italia   (Italy)

Author keywords

Anemia; Erythropoietin; Exercise; Fatigue; Quality of life

Indexed keywords

ALPHA INTERFERON; ANTIDEPRESSANT AGENT; CAFFEINE; CISPLATIN; DEXAMPHETAMINE; DOCETAXEL; FLUDARABINE; HYPNOTIC AGENT; IFOSFAMIDE; IRINOTECAN; METHOTREXATE; METHYLPHENIDATE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PACLITAXEL; PSYCHOSTIMULANT AGENT; RALTITREXED; RECOMBINANT ERYTHROPOIETIN; VINCRISTINE;

ANEMIA; ANOREXIA; CANCER; CANCER CHEMOTHERAPY; CANCER PAIN; CANCER RADIOTHERAPY; CLINICAL TRIAL; EUPHORIA; EXERCISE; FATIGUE; HEART DISEASE; HUMAN; INSOMNIA; MENTAL INSTABILITY; NAUSEA; PARANOIA; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; VALIDATION PROCESS; VOMITING;

ANTINEOPLASTIC AGENTS; FATIGUE; HUMANS; NEOPLASMS; PRACTICE GUIDELINES; PREVALENCE; QUALITY OF LIFE;

EID: 0142150112     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11742     Document Type: Review

References (131)

1. Vozelgang NJ, Breitbart W, Cella D, et al. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. Semin Hematol. 1997;34:4-12.
2. Curt GA, Breitbart W, Cella D, et al. Impact of cancer-related fatigue on the lives of patients: new findings from the fatigue coalition. Oncologist. 2000;5:353-360.
3. Sobrero A, Pugliesi F, Guglielmi A, et al. Fatigue: a main component of anemia symptomatology. Semin Hematol. 2001;28:15-18.
4. Mock V, Atkinson A, Barsevick A, et al. National Comprehensive Cancer Network. NCNN practice guidelines for cancer-related fatigue. Oncology. 2000;14:151-61.
5. Glaus A, Crow R, Hammond S. A qualitative study to explore the concept of fatigue/tiredness in cancer patients and in healthy individuals. Support Care Cancer. 1996;4:82-86.
6. Fukuda K, Straus SE, Hickie I, et al. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med. 1994;121:953-959.
7. Cella D, Peterman A, Passik S, et al. Progress toward guidelines for the management of fatigue. Oncology. 1998;12:369-377.
8. Flechtner H, Bottomley A. Fatigue and quality of life: lessons from the real world. Oncologist. 2003;8(Suppl 1):5-9.
9. de Jong N, Courtens AM, Abu-Saad HH, Schouten HC. Fatigue in patients with breast cancer receiving adjuvant chemotherapy: a review of the literature. Cancer Nurs. 2002;25: 283-297.
10. Broeckel JA, Jacobsen PB, Horton J, et al. Characteristics and correlates of fatigue after adjuvant chemotherapy for breast cancer. J Clin Oncol. 1998;16:1689-1696.
11. Morrow GR, Andrews PL, Hickok JT, Roscoe JA, Matteson S. Fatigue associated with cancer and its treatment. Support Care Cancer. 2002;10:389-398.
12. Portenoy RK, Thaler HT, Kornblith AB, et al. Pain in ovarian cancer: prevalence, characteristics, and associated symptoms. Cancer. 1994;74:907-915.
13. Holzner B, Kemmler G, Meraner V, et al. Fatigue in ovarian carcinoma patients. Cancer. 2003;15;97:1564-1572.
14. Gutstein HB. The biologic basis of fatigue. Cancer. 2001; 92(Suppl 1):1678-1683.
15. Ottenweller JE, Natelson BH, Gause WC, et al. Mouse running activity is lowered by brucella abortus treatment: a potential model to study chronic fatigue. Physiol Behav. 1998;63:795-801.
16. Knox LS, Crosby LO, Feurer ID, Buzby GP, Miller CL, Mullen JL. Energy expenditure in malnourished cancer patients. Ann Surg. 1983;197:152-162.
17. Fredrix EWHM, Soeters PB, Wouters EFM, Deerenberg IM, von Meyenfeldt MF, Saris WHM. Effect of different tumor types on resting energy expenditure. Cancer Res. 1991;51: 6138-6141.
18. Gibney E, Jennings G, Jebb SA, Murgatroyd PR, Elia M. Measurement of total energy expenditure in patients with lung cancer and validation of the bicarbonate-urea method against whole-body indirect calorimetry. Proc Nutr Soc. 1997;56:226A.
19. Lundholm K, Holm G, Scherstén T. Insulin resistance in patients with cancer. Cancer Res. 1978;38:4665-4670.
20. Edén E, Edström S, Bennegård K, Scherstén T, Lundholm K. Glucose flux in relation to energy expenditure in malnourished patients with and without cancer during periods of fasting and feeding. Cancer Res. 1984;44:1718-1724.
21. Shaw JHF, Wolfe RR. Glucose and urea kinetics in patients with early and advanced gastrointestinal cancer: the response to glucose infusion, parenteral feeding, and surgical resection. Surgery. 1987;101:181-191.
22. Jeevanandam M, Horowitz GD, Lowry SF, Brennan MF. Cancer cachexia and protein metabolism. Lancet. 1984;i: 1423-1426.
23. Fearon KCH, Hansell DT, Preston T, et al. Influence of whole body protein turnover rate on resting energy expenditure in patients with cancer. Cancer Res. 1988;48:2590-2595.
24. Emery PW, Edwards RHT, Rennie MJ, Souhami RL, Halliday D. Protein synthesis in muscle measured in vivo in cachectic patients with cancer. Br Med J. 1984;289:584-586.
25. Dworzak F, Ferrari P, Gavazzi C, Maiorana C, Bozzeti F. Effects of cachexia due to cancer on whole body and skeletal muscle protein turnover. Cancer. 1998;82:42-48.
26. Blay YJ, Negrier S, Combaret V, Attali S, Goillot E. Serum level of interleukin-6 as a prognostic factor in metastatic renal cell carcinoma. Cancer Res. 1992;52:3317-3322.
27. Falconer JS, Fearon KCH, Plester CE, Ross JA, Carter DC. Cytokines, the acute-phase response, and resting energy expenditure in cachectic patients with pancreatic cancer. Ann Surg. 1994;219:325-331.
28. Staal-van den Brekel AJ, Dentener MA, Schols AMWJ, Buurman WA, Wouters EFM. Increased resting energy expenditure and weight loss are related to a systemic inflammatory response in lung cancer patients. J Clin Oncol. 1995;13: 2600-2605.
29. Wayman J, O'Hanlon D, Hayes N, Shaw I, Griffin SM. Fibrinogen levels correlate with stage of disease in patients with oesophageal cancer. Br J Surg. 1997;84:185-188.
30. Scott HR, McMillan DC, Crilly A, McArdle CS, Milroy R. The relationship between weight loss and interleukin 6 in non-small-cell lung cancer. Br J Cancer. 1996;73:1560-1562.
31. Simons JPFHA, Schols AMWJ, Buurman WA, Wouters EFM. Weight loss and low body cell mass in males with lung cancer: relationship with systemic inflammation, acute-phase response, resting energy expenditure, and catabolic and anabolic hormones. Clin Sci. 1999;97:215-223.
32. Reeds PJ, Fjeld CR, Jahoor F. Do the differences between the amino acid compositions of acute-phase and muscle proteins have a bearing on nitrogen loss in traumatic states? J Nutr. 1994;124:906-910.
33. Mitch WE, Goldberg AL. Mechanisms of muscle wasting: the role of the ubiquitin-proteasome pathway. N Engl J Med. 1996;335:1897-1905.
34. Baracos V, DeVivo C, Hoyle DHR, Goldberg AL. Activation of the ATP-ubiquitin-proteosome pathway in skeletal muscle of cachectic rats bearing a hepatoma. Am J Physiol. 1995; 268:E996-E1006.
35. Llovera M, García-Martínez C, Agell N, Ló pez-Soriano FJ, Argilés JM. Muscle wasting associated with cancer cachexia is linked to an important activation of the ATP-dependent ubiquitin-mediated proteolysis. Int J Cancer. 1995;61:138-141.
36. Williams A, Sun X, Fischer JE, Hasselgren PO. The expression of genes in the ubiquitin-proteosome proteolytic pathway is increased in skeletal muscle from patients with cancer. Surgery. 1999;126:744-749.
37. Bossola M, Muscaritoli M, Costelli P, et al. Increased muscle ubiquitin mRNA levels in gastric cancer patients. Am J Physiol. 2001;280:R1518-R1523.
38. Gomes MD, Lecker SH, Jagoe RT, Navon A, Goldberg AL. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc Natl Acad Sci USA. 2001;98: 14440-14445.
39. Selby P, Hobbs S, Viner C, et al. Tumour necrosis factor in man: clinical and biological observations. Br J Cancer. 1987; 56:803-808.
40. Moldawer LL, Andersson C, Gelin J, Lundholm KG. Regulation of food intake and hepatic protein synthesis by recombinant-derived cytokines. Am J Physiol. 1988;254:G450-G456.
41. Starnes HF, Warren RS, Jeevanandam M, et al. Tumor necrosis factor and the acute metabolic response to tissue injury in man. J Clin Invest. 1988;82:1321-1325.
42. Hellerstein MK, Meydani SN, Meydani M, Wu K, Dinarello CA. Interleukin-1-induced anorexia in the rat. Influence of prostaglandins. J Clin Invest. 1989;84:228-235.
43. Castell W, Gómez-Lechón MJ, David M, Fabra R, Trullenque R, Heinrich PC. Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology. 1990;12:1179-1186.
44. Ballmer PE, McNurlan MA, Southorn BG, Grant I, Garlick PJ. Effects of human recombinant interleukin-1 beta on protein synthesis in rat tissues compared with a classical acute-phase reaction induced by turpentine. Biochem J. 1991;279: 683-688.
45. Fearon KCH, McMillan DC, Preston T, Winstanley FP, Cruikshank AM, Henkin A. Elevated circulating interleukin-6 is associated with an acute-phase response but reduced fixed hepatic protein synthesis in patients with cancer. Ann Surg. 1991;213:26-31.
46. Okusawa S, Gelfand JA, Ikejima T, Connolly RJ, Dinarello CA. Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. J Clin Invest. 1988;81:1162-1172.
47. Rothwell NJ. Eicosanoids, thermogenesis and thermoregulation. Prostaglandins Leukot Essent Fatty Acids. 1992;46:1-7.
48. Kozak W, Soszynski D, Rudolph K, Conn CA, Kluger MJ. Dietary n-3 fatty acids differentially affect sickness behaviour in mice during local and systemic inflammation. Am J Physiol. 1997;272:R1298-R1307.
49. Hellerstein MK, Meydani SN, Meydani M, Wu K, Dinarello CA. Interleukin-1-induced anorexia in the rat. Influence of prostaglandins. J Clin Invest. 1989;84:228-235.
50. Uehara A, Ishikawa Y, Okumura T, et al. Indomethacin blocks the anorexia action of interleukin-1. Eur J Pharmacol. 1989;170:257-260.
51. Thompson MG, Palmer RM. Signalling pathways regulating protein turnover in skeletal muscle. Cell Signal. 1998;10:1-11.
52. Todorov P, Cariuk P, McDevitt T, Coles B, Fearon K, Tisdale M. Characterisation of a cancer cachectic factor. Nature. 1996;379:739-742.
53. Lorite MJ, Smith HJ, Arnold JA, Morris A, Thomson MG, Tisdale MJ. Activation of ATP-ubiquitin-dependent proteolysis in skeletal muscle in vivo and murine myoblasts in vitro by a proteolysis-inducing factor. Br J Cancer. 2001;85:297-302.
54. Watchorn TM, Waddell I, Dowidar N, Ross JA. Proteolysis-inducing factor regulates hepatic gene expression via the transcription factors NF-kappa B and STAT3. FASEB J. 2001; 155:562-564.
55. Watchorn TM, Waddell I, Ross JA. Proteolysis-inducing factor differentially influences transcriptional regulation in endothelial subtypes. Am J Physiol. 2002;282:E763-E769.
56. Cabal-Manzano R, Bhargava P, Torres-Duarte A, Marshall J, Bhargava P, Wainer IW. Proteolysis-inducing factor is expressed in tumours of patients with gastrointestinal cancers and correlates with weight loss. Br J Cancer. 2001;84:1599-1601.
57. Fujiki F, Mukaida N, Hirose K, et al. Prevention of adenocarcinoma colon 26-induced cachexia by interleukin 10 gene transfer. Cancer Res. 1997;57:94-99.
58. Westerblad H. Recent advances in the understanding of skeletal muscle fatigue. Curr Opin Rheumatol. 2002;14:648-652.
59. Checkley S. The neuroendocrinology of depression and chronic stress. Br Med Bull. 1996;52:597-617.
60. Scott LV, Dinan TG. The neuroendocrinology of chronic fatigue syndrome: focus on the hypothalamic-pituitary-adrenal axis. Funct Neurol. 1999;14:3-11.
61. Inui A. Cancer anorexia-cachexia syndrome: are neuropeptides the key? Cancer Res. 1999;59:4493-4501.
62. McEwen BS. Protective and damaging effects of stress mediators: the good and bad sides of the response to stress. Metabolism. 2002;51:2-4.
63. Stone P, Richards M, Hardy J. Fatigue in patients with cancer. Eur J Cancer. 1998;34:1670-1676.
64. Stone P, Hardy J, Huddart R, A'Hern R, Richards M. Fatigue in patients with prostate cancer receiving hormone therapy. Eur J Cancer. 2000;36:1134-1141.
65. Smets EM, Garssen B, Schuster-Uitterhoeve AL, de Haes JC. Fatigue in cancer patients. Br J Cancer. 1993;68:220-224.
66. Larson PJ, Lindsey AM, Dodd MJ, et al. Influence of age on problems experienced by patients with lung cancer undergoing radiation therapy. Oncol Nurs Forum. 1993;20:473-480.
67. Smets EM, Visser MR, Willems-Groot AF, Garssen B, Schuster-Uitterhoeve AL, de Haes JC. Fatigue and radiotherapy: (B) experience in patients 9 months following treatment. Br J Cancer. 1998;78:907-912.
68. Jereczek-Fossa BA, Marsiglia HR, Orecchia R. Radiotherapy-related fatigue. Crit Rev Oncol Hematol. 2002;41:317-325.
69. Fobair P, Hoppe RT, Bloom J, et al. Psychosocial problems among survivors of Hodgkin's disease. J Clin Oncol. 1986;4: 805-814.
70. Piper BF, Rieger PT, Brophy L, et al. Recent advances in the management of biotherapy-related side effects: fatigue. Oncol Nurs Forum. 1989;16:27-34.
71. Jones T, Wadler S, Hupart K. Endocrine-mediated mechanisms of fatigue during treatment with interferon-alpha. Semin Oncol. 1998;25(Suppl 1):54-63.
72. Kirkwood JM, Bender C, Agarwala S, et al. Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy. J Clin Oncol. 2002;20(17):3703-3718.
73. McDaniel JS, Musselman DL, Porter MR, et al. Depression in patients with cancer: diagnosis, biology, and treatment. Arch Gen Psychiatr. 1995;52:89-99.
74. Loge JH, Abrabamsen AF, Ekeberg Ø, et al. Fatigue and psychiatric morbidity among Hodgkin's disease survivors. J Pain Symptom Manage. 2000;19:91-99.
75. Hopwood P, Stephens RJ. Depression in patients with lung cancer: prevalence and risk factors derived from quality-of-life data. J Clin Oncol. 2000;18:893-903.
76. Visser MR, Smets EM. Fatigue, depression and quality of life in cancer patients: how are they related? Support Care Cancer. 1998;6:101-108.
77. Okuyama T, Akechi T, Kugaya A, et al. Factors correlated with fatigue in disease-free breast cancer patients: application of the Cancer Fatigue Scale. Support Care Cancer. 2000; 8:215-222.
78. Leonard B. Stress, depression and the activation of the immune system. World J Biol Psychiatr. 2000;1:17-25.
79. Macdonald DR. Neurotoxicity of chemotherapeutic agents. In: Perry MC, editor. The chemotherapy sourcebook, 2nd ed. Baltimore: Williams and Wilkins, 1996:745-765.
80. Posner JB. Side effects of chemotherapy. In: Posner JB, editor. Neurologic complications of cancer. Philadelphia: FA Davis Company, 1995:282-310.
81. Mock V, Atkinson A, Barsevick A, et al. NCCN clinical practice guidelines for cancer-related fatigue, version 1.2003. Available from URL: http://www.nccn.org/physician_gls/index.html. To view the most recent version of the guideline, go online to www.nccn.org [access date June 1, 2003].
82. Canaris GJ, Manowitz NR, Mayor G, et al. The Colorado Thyroid Disease Prevalence Study. Arch Intern Med. 2000; 160:526-534.
83. Vanderpump MP, Tunbridge WM. Epidemiology and prevention of clinical and subclinical hypothyroidism. Thyroid. 2002;12:839-847.
84. Mercado G, Adelstein DJ, Saxton JP, Secic M, Larto MA, Lavertu P. Hypothyroidism: a frequent event after radiotherapy and after radiotherapy with chemotherapy for patients with head and neck carcinoma. Cancer. 2001;92:2892-2897.
85. Knobel H, Havard Loge J, Brit Lund M, Forfang K, Nome O, Kaasa S. Late medical complications and fatigue in Hodgkin's disease survivors. J Clin Oncol. 2001;19:3226-3233.
86. Cazzola M. Mechanisms of anaemia in patients with malignancy: implications for the clinical use of recombinant human erythropoietin. Med Oncol. 2000;17(Suppl 1):S11-S16.
87. Seidenfeld J, Piper M, Flamm C, et al. Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst. 2001;93:1204-1214.
88. Bruera E, Brenneis C, Michaud M, et al. Association between asthenia and nutritional status, lean body mass, anemia, psychological status, and tumor mass in patients with advanced breast cancer. J Pain Symptom Manage. 1989;4:59-63.
89. Morant R. Asthenia: an important symptom in cancer patients. Cancer Treat Rev. 1996(Suppl A);22:117-122.
90. Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol. 1997(Suppl 2);34:13-19.
91. Yellen SB, Cella DF, Webster K, et al. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy measuring system. J Pain Symptom Manage. 1997;13:63-74.
92. Cella D, Peterman A, Passik S, et al. Progress toward guidelines for the management of fatigue. Oncology. 1998;12:369-377.
93. Portenoy RK, Itri LM. Cancer-related fatigue: guidelines for evaluation and management. Oncologist. 1999;4:1-10.
94. Cella D, Davis K, Breitbart W, Curt G. Cancer-related fatigue: prevalence of proposed diagnostic criteria in a United States sample of cancer survivors. J Clin Oncol. 2001;19:3385-3391.
95. McNair DM, Lorr M, Droppleman LF. EdITS manual for the Profile of Mood States. San Diego: Educational and Industrial Testing Service, 1971.
96. McCormack HM, de L Horne DJ, Sheather S. Clinical applications of visual analog scales: a critical review. Psychol Med. 1998;10:1007-1019.
97. Piper BF. Piper fatigue scale available for clinical testing. Oncol Nurs Forum. 1990;17:661-662.
98. Piper BF, Dibble SL, Dodd MJ, Weiss MC, Slaughter RE, Paul SM. The revised Piper Fatigue Scale: psychometric evaluation in women with breast cancer. Oncol Nurs Forum. 1998; 25:677-684.
99. Mendoza TR, Wang XS, Cleeland CS, et al. The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer. 1999;85:1186-1196.
100. Okuyama T, Akechi T, Kugaya A. Development and validation of the Cancer Fatigue Scale: a brief, three-dimensional, self-rating scale for assessment of fatigue in cancer patients. J Pain Symptom Manage. 2000;19:5-14.
101. Schwartz JE, Jandorf L, Krupp LB. The measurement of fatigue: a new instrument. J Psychosom Res. 1993;37:753-762.
102. Smets EM, Garssen B, Bonke B, De Haes JC. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res. 1995; 39:315-325.
103. Cella D, Nowinski CJ. Measuring quality of life in chronic illness: the functional assessment of chronic illness therapy measurement system. Arch Phys Med Rehabil. 2002;83(12 Suppl 2):S10-S17.
104. Cella D, Lai JS, Chang CH, Peterman A, Slavin M. Fatigue in cancer patients compared with fatigue in the general United States population. Cancer. 2002;94:528-538.
105. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:364-376.
106. Kemmler G, Holzner B, Kopp M, et al. Comparison of two quality-of-life instruments for cancer patients: the Functional Assessment of Cancer Therapy-General and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30. J Clin Oncol. 1999;17: 2932-2940.
107. Stone P, Richardson A, Ream E, et al. Cancer-related fatigue: inevitable, unimportant and untreatable? Results of a multicentre patient survey. Ann Oncol. 2000;11:971-975.
108. Abels R. Erythropoietin for anemia in cancer patients. Eur J Cancer. 1993;29A(Suppl 2):S2-S8.
109. Ludwig H, Sundal E, Pecherstorfer M, et al. Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy. Cancer. 1995;76:2319-2329.
110. Dunphy FR, Dunleavy TL, Harrison BR, et al. Erythropoietin reduces anemia and transfusions after chemotherapy with paclitaxel and carboplatin. Cancer. 1997;79:1623-1628.
111. Demetri GD, Kris M, Wade J, Degos L, Cella D. Quality of life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. J Clin Oncol. 1998;16:3412-3425.
112. Glaspy J, Bukowski R, Steinberg D, et al. Impact of therapy with epoetin alfa on clinical outcomes in patients with non-myeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol. 1997;15:1218-1234.
113. Gabrilove JL, Cleeland CS, Livingston RB, et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol. 2001;19:2875-2882.
114. Crawford J, Cella D, Cleeland CS, et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer. 2002;95:888-895.
115. Littlewood TJ, Bajetta E, Nortier JWR, Vercammen E, Rapaport B, for the Epoietin Alfa Study Group. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2001;19:2865-2874.
116. Quirt I, Robeson C, Lau CY, et al. Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy. J Clin Oncol. 2001;19:4126-4134.
117. Kotasek D, the Darbepoetin Alfa 980291 Study Group, Berg R, et al. Randomized, double-blind, placebo-controlled, Phase I/II dose-finding study of NESP administered once every three weeks in solid tumor patients. Blood. 2000;96: 294a.
118. Smith RE Jr., Jaiyesimi IA, Meza LA, et al. Novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia of chronic disease associated with cancer. Br J Cancer. 2001; 84(Suppl 1):24-30.
119. Glaspy J, Jadeja JS, Justice G. A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy. Br J Cancer. 2001;84(Suppl 1):17-23.
120. Hedenus M, Hansen S, Taylor K, et al. Randomised, dose-finding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies. Br J Haematol. 2002;119: 79-86.
121. Vansteenkiste J, Pirker R, Massuti B, et al. Double-blind, placebo-controlled, randomized Phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst. 2002;94:1211-1220.
122. Bruera E, Macmillan K, Kuehn N, Hanson J, MacDonald RN. A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status, and other symptoms in patients with advanced cancer. Cancer. 1990;66:1279-1282.
123. Bruera E, Roca E, Cedaro L, Carraro S, Chacon R. Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study. Cancer Treat Rep. 1985;69:751-754.
124. Puccio M, Nathanson L. The cancer cachexia syndrome. Semin Oncol. 1997;24:277-287.
125. Mock V, Burke MB, Sheehan PK, et al. A nursing rehabilitation program for women with breast cancer receiving adjuvant chemotherapy. Oncol Nurs Forum. 1994;21:899-908.
126. Mock V, Dow KH, Meares C, et al. Effects of exercise on fatigue, physical functioning, and emotional distress during radiation therapy for breast cancer. Oncol Nurs Forum. 1997;24:991-1000.
127. Dimeo FC, Stieglitz R-D, Novelli-Fisher U, et al. Effects of physical activity on the fatigue and psychologic status of cancer patients during chemotherapy. Cancer. 1999;85: 2273-2277.
128. Schwartz AL. Daily fatigue patterns and effect of exercise in women with breast cancer. Cancer Pract. 2000;8:16-24.
129. Schwartz AL, Mori M, Gao R, et al. Exercise reduces daily fatigue in women with breast cancer receiving chemotherapy. Med Sci Sports Exerc. 2001;33:718-723.
130. Mock V, Pickett M, Ropka ME, et al. Fatigue and quality of life outcomes of exercise during cancer treatment. Cancer Pract. 2001;9:119-127.
131. Schwartz AL, Thompson JA, Masood N. Interferon-induced fatigue in patients with melanoma: a pilot study of exercise and methylphenidate. Oncol Nurs Forum. 2002;29:E85-E90.